Perspectives on How Philanthropy and Venture Capital Must Partner to Translate Lab Discoveries Into Meaningful Benefits for Alzheimer’s Disease Patients

Posted April 8, 2022

In this webinar, Dr. Vince Groppi, CEO of Oricula Therapeutics and member of the Cure Alzheimer’s Fund Research Strategy Council, discussed his perspectives with Meg Smith, EVP of CureAlz Research Management, on how philanthropy and venture capital must partner to translate lab discoveries into meaningful benefits for patients with Alzheimer’s disease. VIEW THE RECORDING OF THE WEBINAR BELOW.



Vince Groppi, Ph.D., CEO, Oricula Therapeutics
Meg Smith, Executive Vice President Research Management, Cure Alzheimer’s Fund

Honorary Co-Chairs:

Thank you to our co-founders and honorary co-chairs for this event.
Henry McCance, Chairman Emeritus, Greylock Partners
Jacqui Morby, Senior Advisor, TA Associates

( Vince Groppi, Ph.D. | Meg Smith | Henry McCance | Jacqui Morby )


And a special thank you to the members of our Honorary Host Committee for their support of this event!

Honorary Host Committee:

Sam Brasch, Convey Capital
Jeff Chambers, TA Associates
David Dolby, Dolby Family Ventures
Matt Kelliher, Tech Coast Angels